Nucor Corporation reports Q1 2026 results on April 28 with the stock trading at its most stretched technical reading in over a year — and options markets pricing in more hedging than any point in recent memory.
The options signal is hard to miss. The put/call ratio jumped to 0.70 on the day before the print, nearly 2.6 standard deviations above its 20-day average of 0.50 — the highest defensive lean in the past year against a 52-week PCR range of 0.38 to 0.91. That caution follows a stunning 32% rally over the past month to $215, and a 6.3% gain in the final week alone. The RSI has climbed to 83, a level that historically reflects a stock stretched well beyond normal momentum. Investors appear to be buying insurance on a stock that has run very hard, very fast.
Short sellers are not pressing the trade. Short interest is just 1.9% of the free float — barely moved over the past month — with borrowing costs near rock-bottom at 0.31% and utilization at under 1%, a fraction of its 52-week peak of 6.15%. There is no evidence of a coordinated short thesis building into the print. The low borrow cost and thin utilization suggest the lending market is untaxed and any shorts are largely tactical. This is not a crowded bearish setup.
The analyst debate has shifted meaningfully bullish ahead of the print. Wells Fargo's Timna Tanners and JP Morgan's Bill Peterson both raised targets in the two weeks prior — to $213 and $212 respectively — while maintaining Overweight ratings. UBS upgraded to Buy from Neutral in late March, though its $190 target now sits well below the current price. The consensus mean target is $197, implying the stock has already exceeded what most Street models had priced in. Forward earnings momentum ranks in the 87th percentile on a 12-month YoY basis, and the dividend score is exceptionally high at 93rd percentile — two pillars of the bull case. Bears can point to an EV/EBITDA of 9.2x with a negative analyst return potential of -10% at current prices, meaning consensus thinks the rally has overshot. The CEO, Leon Topalian, sold roughly $1.9 million in shares in late March near $162 — well below current levels, but worth noting as the only significant insider activity in recent months.
The print will test whether Q1 volumes and pricing justify a stock that has re-rated 32% in a month and now trades above every major analyst target on the board.
See the live data behind this article on ORTEX.
Open NUE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
